Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT02544425
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2018-11-14
- Lead Sponsor
- University of Washington
- Registration Number
- NCT02538926
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
- Conditions
- Interventions
- First Posted Date
- 2015-08-13
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 280
- Registration Number
- NCT02521493
- Locations
- 🇨🇦
CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL), Quebec, Canada
🇳🇿Starship Children's Hospital, Grafton, Auckland, New Zealand
🇳🇿Christchurch Hospital, Christchurch, New Zealand
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationBiological: BlinatumomabDrug: AsparaginaseDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneOther: Pharmacological StudyDrug: EtoposideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: MethotrexateDrug: MitoxantroneDrug: Mitoxantrone HydrochlorideRadiation: Radiation TherapyDrug: PegaspargaseDrug: Therapeutic HydrocortisoneDrug: ThioguanineDrug: VincristineDrug: Vincristine Sulfate
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 669
- Registration Number
- NCT02101853
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸NYP/Weill Cornell Medical Center, New York, New York, United States
🇺🇸State University of New York Upstate Medical University, Syracuse, New York, United States
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 107
- Registration Number
- NCT02036489
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Barcelona, Spain
GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- ERYtech Pharma
- Target Recruit Count
- 85
- Registration Number
- NCT01518517
- Locations
- 🇧🇪
Hopital Des Enfants Reine Fabiola, Bruxelles, Belgium
🇧🇪Chr de La Citadelle, Liege, Belgium
🇫🇷Hopital Saint Jacques, Besancon, France
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1645
- Registration Number
- NCT01371981
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Blank Children's Hospital, Des Moines, Iowa, United States
🇺🇸Albany Medical Center, Albany, New York, United States
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT01358253
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 573
- Registration Number
- NCT01230983
Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2010-07-05
- Last Posted Date
- 2021-09-13
- Target Recruit Count
- 76
- Registration Number
- NCT01156883
- Locations
- 🇮🇹
Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy
🇮🇹USL 8 - Ospedale S.Donato, Arezzo, Italy
🇮🇹UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.